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Abstract
Background: Antibacterial activity is a novel function of high-mobility group box 1 (HMGB1).
However, the functional site for this new effect is presently unknown.
Methods and Results: In this study, recombinant human HMGB1 A box and B box (rHMGB1 A
box, rHMGB1 B box), recombinant human HMGB1 (rHMGB1) and the truncated C-terminal acidic
tail mutant (tHMGB1) were prepared by the prokaryotic expression system. The C-terminal acidic
tail (C peptide) was synthesized, which was composed of 30 amino acid residues. Antibacterial
assays showed that both the full length rHMGB1 and the synthetic C peptide alone could efficiently
inhibit bacteria proliferation, but rHMGB1 A box and B box, and tHMGB1 lacking the C-terminal
acidic tail had no antibacterial function. These results suggest that C-terminal acidic tail is the key
region for the antibacterial activity of HMGB1. Furthermore, we prepared eleven different deleted
mutants lacking several amino acid residues in C-terminal acidic tail of HMGB1. Antibacterial assays
of these mutants demonstrate that the amino acid residues 201-205 in C-terminal acidic tail region
is the core functional site for the antibacterial activity of the molecule.
Conclusion: In sum, these results define the key region and the crucial site in HMGB1 for its
antibacterial function, which is helpful to illustrating the antibacterial mechanisms of HMGB1.
Background
High-mobility group box 1(HMGB1) belongs to high-
mobility group superfamily named for its characteristic
rapid mobility in polyacrylamide gel electrophoresis
(PAGE) [1]. It is highly conserved across species and
wildly distribute in eukaryotic cells from yeast to human
[2-4]. Structurally, human HMGB1 has 215 amino acid
residues, including three main functional domains (A
box, B box and a highly conservation, repetitive C termi-
nus). The C terminus is also called C-terminal acidic tail
because it is full of acidic amino acid residues such as
aspartate and glutamic acid [5-8].
HMGB1 is an endogenous nuclear protein that can be
translocated to the cytoplasm and then released extracel-
lularly. In the nucleus, HMGB1 binds to DNA which func-
tions as a co-factor critical for proper transcriptional
regulation and DNA repair [9-14]. Cytoplasmal and extra-
cellular HMGB1 has been extensively related to the
growth of neurite, malignant tumor metastasis, arthero-
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sclerosis and vascellum restenosis [15-23]. HMGB1 is also
detected in serum of patients with sepsis. Thus, it has been
identified as a late mediator of endotoxin lethality, which
plays a critical role in the processes of many kinds of acute
and chronic inflammation[24,25]. Recently it is reported
that the cytoplasmal and extracellular HMGB1 can act as
an antibacterial factor, which is a novel function of the
molecule[26,27]. In physiological situation, as a potent
antibacterial protein, HMGB1 is an important part of
innate immunity defensive barrier of the human body
that can resist bacterial infection in vivo. However, the
functional site for this new effect is presently unknown.
The goal of this study was to determine which region is
mainly responsible for the antibacterial activity of
HMGB1. We showed that the recombinant human
HMGB1 (rHMGB1) and the synthetic C-terminal acidic
tail (C peptide) presented antibacterial activity, neverthe-
less, the A box, B box domains of the molecule and the
truncated HMGB1 lacking its C-terminal acidic tail failed
to inhibit bacterial multiplication, which demonstrated
that the C-terminal acidic tail is the key region for the anti-
bacterial activity of HMGB1. We further showed that the
amino acid residues 201-205 in C-terminal acidic tail
region play a crucial role in antibacterial function of
HMGB1. Therefore, our study defines the key region and
the crucial site in HMGB1 for its antibacterial activity,
which may provide important insights to antibacterial
mechanisms of the molecule.
Materials and methods
Preparation of recombinant proteins and C peptide
A diagram of recombinant proteins and C peptide used in
this work was shown in Figure 1. The cDNA encoding
rHMGB1 was cloned by reverse transcription-polymerase
chain reaction (RT-PCR) with total RNA extracted by TRI-
ZOL reagent (Invitrogen) from human peripheral blood
mononuclear cell (PBMC) [22,28]. Then the purified PCR
product was cloned into pUC19, and the recombinant
plasmid was named pUC19-rHMGB1. The DNA
sequences encoding rHMGB1 A box, B box, tHMGB1 and
mHMGB1 -211-215, mHMGB1 - 206-215, mHMGB1 -
201-215, mHMGB1 -196-215, mHMGB1 -191-215
(rHMGB1 lacking amino acid residues 211-215, 206-215,
201-215, 196-215 and 191-215 respectively) were gener-
ated by PCR taking pUC19-rHMGB1 as template. The
DNA sequences encoding mHMGB1 -186-200, mHMGB1
-196-210, mHMGB1 -196-205, mHMGB1 -198-207,
mHMGB1 -201-210 and mHMGB1 -201-205 (rHMGB1
lacking amino acid residues 186-200, 196-210, 196-205,
198-207, 201-210 and 201-205 respectively) were ampli-
fied by one-step opposite-direction PCR using
MutanBEST Kit (TaKaRa) according to the manufacturer's
instructions (taking pUC19-rHMGB1 as template). The
primers used in this study were listed in Table 1. After
being sequenced, the fragments encoding rHMGB1 A box
and B box were separately ligated into the Kpn I/HindIII
cloning sites in the pQE-80L/DHFR prokaryotic expres-
sion vector (pQE-80L/DHFR vector constructed by us
from pQE-80L). Other fragments were cloned into the
Kpn I/HindIII sites of pQE-80L vector. Then, all of these
prokaryotic expression vectors were separately trans-
formed into E. coli DH5 and induced by IPTG to express
the corresponding His-tagged proteins, which were deter-
mined by Western blot. Briefly, the lysates of E. coli DH5
expressing the corresponding proteins were subjected to
SDS-PAGE and then transferred onto polyvinylidene dif-
luoride membranes (Pierce). After blocked with 5% non-
fat milk in phosphate buffered saline containing 0.1%
Tween 20 (PBS-T), the membranes were incubated with
mouse anti-His monoclonal antibody (Qiagen). Then
washed with PBS-T, the membranes were incubated with
horseradish peroxidase-labeled goat anti-mouse IgG
(Pierce). After washed the immunoreactive proteins were
visualized by DAB. The expressed proteins were purified
by Ni2+-NTA chromatography kit (Qiagen) under the nat-
ural condition following the instructions of the manufac-
turer. The C peptide was synthesized by SciLight
Biotechnology, LLC.
Antibacterial assay with bacterial dilution in the test tubes
Briefly, the bacteria were grown overnight at 37°C in
Luria-Bertani (LB) agar plate, and the fresh single clone of
the bacteria was picked up and inoculated into LB liquid
medium, shaking cultivated at 37°C until the optical den-
sity at 600 nm (OD600) reaching 0.4. Five microliter aliq-
uot of the bacteria was 1:1000 diluted in each tube
containing LB liquid medium, and then the tested recom-
binant protein or C peptide was added into different tubes
at a final concentration of 0, 2, 4, 6, 8 and 10 mol/L.
After shaking cultivated at 37°C for 8 hours, the OD600 of
the bacteria was measured using a spectrophotometer.
Each experiment was performed in triplicate and repeated
three times. DHFR protein purified by the same system
was used as a negative control. The bacteria used in this
experiment included Staphylococcus aureus (SA),  E. coli
JM109 (JM109), E. coli ATCC 25922 (ATCC 25922), E. coli
DH5 (DH5) and Pseudomonas aeruginosa (PA).
Antibacterial assay with dispersion method
Briefly, the double-layer LB agar plates were prepared (the
upper layer containing 50 l bacteria with OD600 = 0.4
and 7 g/L agar, the nether layer with agar at 15 g/L). The
holes in the upper layer of the plate were made by a sterile
hoop with a diameter of 5 mm. Then tested recombinant
protein or C peptide was loaded into the holes (300
nmol/hole). After incubation at 37°C for 8 hours, the
diameters of the zones of growth inhibition were meas-
ured as reflections of the ability of the corresponding pro-
tein or C peptide to inhibit the bacteria multiplication.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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DHFR protein purified by the same system was used as a
negative control. The bacteria used in this experiment
were same as in "Antibacterial assay with bacterial dilution in
the test tubes".
Statistical analysis
Data were plotted as mean ± standard deviation and nor-
malized relative to the negative control. Comparison
between data sets obtained for different recombinant pro-
teins and peptide were performed with one-way ANOVA
using software SPSS13.0.
Results
Preparation of recombinant proteins
Totally 16 recombinant proteins were prepared in this
study (a schematic description of the recombinant pro-
teins was shown in Figure 1), including rHMGB1,
tHMGB1, rHMGB1 A box, rHMGB1 B box, eleven differ-
ent deleted mutants lacking several amino acid residues in
C-terminal acidic tail of HMGB1 (rHMGB1 lacking amino
acid residues 211-215, 206-215, 201-215, 196-215, 191-
215, 186-200, 196-210, 196-205, 198-207, 201-210 and
201-205 respectively) and negative control protein DHFR.
All the 16 proteins were 6×His-tagged because of the char-
acteristics of the expression vector pQE-80L, which can
result in a 6×His-tag added in N-terminal of the recom-
binant proteins. The expressed proteins by E. coli DH5
were confirmed by western blot with anti-His antibody
(as shown in Figure 2). After purified by Ni2+-NTA chro-
matography, the purity of the proteins was analyzed by
SDS-PAGE (Figure 3), which could reach 90%-95%. The C
peptide was synthesized and HPLC purified by SciLight
Biotechnology, LLC (Beijing, CHINA) at 96% purity.
C-terminal acidic tail is the key region for the antibacterial 
activity of HMGB1
To examine which region is mainly responsible for the
antibacterial activity of HMGB1, the antibacterial func-
tions of rHMGB1, tHMGB1, rHMGB1 A box and B box,
and C peptide were compared. As shown in Figure 4 and
additional file 1 panel A-F, both the full length rHMGB1
and C peptide alone could inhibit the proliferation of SA,
JM109, ATCC 25922 and DH5 in different extent, but
rHMGB1 A box and B box, and tHMGB1 lacking the C-ter-
minal acidic tail had no effect on the tested bacteria,
which indicated that the C-terminal acidic tail is the key
region for the antibacterial activity of HMGB1. Moreover,
the results also showed that all the above four proteins
Table 1: Primers used for PCR.
Forward primer Reverse primer
rHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTATGTC
A box GCAAAGGAGATC-3' TCCCCTTTGGGAGG-3'
rHMGB1 5'-CTGGTACCATGA 5'-CGCAAGCTTTTAATA
B box AGTTCAAGGATCCC-3' TGCAGCAATATCCT-3'
rHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTATT
GCAAAGGAGATC-3' CATCATCATCATC-3'
tHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTACTT
GCAAAGGAGATC-3' CTTTTTCTTGCT-3'
mHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTATTC
-211~215 GCAAAGGAGATC-3' TTCTTCATCTTC-3'
mHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTAATCTT
-206~215 GCAAAGGAGATC-3' CTTCATCTTCC-3'
mHMGB1 5'-CTGGTACCATGG 5'-CGAAGCTTTTACTC
-201~215 GCAAAGGAGATC-3' CTCCTCCTCATCCT-3'
mHMGB1 5'-CTGGTACCATGG 5'-GCAAGCTTTTACTCTT
-196~215 GCAAAGGAGATC-3' CATCTTCCTCATC-3'
mHMGB1 5'-CTGGTACCATGG 5'-CGCAAGCTTTTAATC
-191~215 GCAAAGGAGATC-3' TTCCTCCTCTTCC-3'
mHMGB1 5'-GAAGATGAAGAA 5'-CTTCTTTTTCTT
-186~200 GATGAAGATGAA-3' GCTTTTTTCAGC-3'
mHMGB1 5'-GATGATGATG 5'-CTCTTCATCTT
-196~210 ATGAATAAAAG-3' CCTCATCTT-3'
mHMGB1 5'-GAAGATGAAGA 5'-CTCTTCATCTT
-196-205 AGAAGATGATG-3' CCTCATCTT-3'
mHMGB1 5'-GAAGAAGAT 5'-CTCATCCTCTTC
-198~207 GATGATGATG-3' ATCTTCCTCAT-3'
mHMGB1 5'-GATGATGATGAT 5'-CTCCTCCTCCT
-201-210 GAATAAAAGC-3' CATCCTCTT-3'
mHMGB1 5'-GAAGATGAAGA 5'-CTCCTCCTCCT
-201~205 AGAAGATGATG-3' CATCCTCTT-3'Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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Schematic descriptions of the structure of the recombinant proteins and C peptide used in this work Figure 1
Schematic descriptions of the structure of the recombinant proteins and C peptide used in this work. Wild type 
human HMGB1 is composed of three domains: A box (amino acid residues 1-85), B boxes (amino acid residues 88-162) and a 
C-terminal acidic tail (amino acid residues 186-215). rHMGB1 is the full length recombinant human HMGB1. tHMGB1 is trun-
cated HMGB1 lacking its C-terminal acidic tail. rHMGB1 A box or rHMGB1 B box is HMGB1 A box or B box fusioned with 
DHFR in order to stabilized express in prokaryotic system. C peptide is the C-terminal acidic tail composed of 30 amino acid 
residues. Eleven different deleted mutants lacking several amino acid residues in C-terminal acidic tail of HMGB1 are mHMGB1 
-211-215, mHMGB1 - 206-215, mHMGB1 -201-215, mHMGB1 -196-215, mHMGB1 -191-215, mHMGB1 -186-200, mHMGB1 
-196-210, mHMGB1 -196-205, mHMGB1 -198-207, mHMGB1 -201-210, and mHMGB1 -201-205. These mutants are recom-
binant human HMGB1 lacking amino acid residues 211-215, 206-215, 201-215, 196-215, 191-215, 186-200, 196-210, 196-205, 
198-207, 201-210 and 201-205 respectively. The sprit shadow stands for the deleted regions.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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and the C peptide failed to inhibit PA multiplication,
which suggested that the sensitivity of different bacteria to
HMGB1 may be distinct.
Amino acid residues 201-205 in C-terminal acidic tail 
region is the core functional site for the antibacterial 
activity of HMGB1
To determine which site in the C-terminal acidic tail
region plays a crucial role in antibacterial activity of
HMGB1, we constructed eleven different deleted mutants
lacking different several amino acid residues in C-terminal
acidic tail region of HMGB1 (as shown in Figure 1). The
antibacterial assay with these mutants showed that three
of them (lacking amino acid residues 211-215, 206-215
and 186-200 respectively) could still exert antibacterial
function on SA, JM109, ATCC25922 and DH5, but the
other eight mutants failed to inhibit any one of the above
bacterial multiplication (Figure 5 and additional file 1
panel F-Q). These results indicated that the amino acid
residues 201-205 in C-terminal acidic tail region is the
core functional site for the antibacterial activity of
HMGB1, which means this site plays a crucial role in the
antibacterial function of the molecule. In addition, simi-
lar with the results in "C-terminal acidic tail is the key region
for the antibacterial activity of HMGB1", all the eleven
mutants had no effect on bacteria PA multiplication.
Discussion
We have primarily demonstrated in this study that the C-
terminal acidic tail is the key region for the antibacterial
activity of HMGB1, and the amino acid residues 201-205
in C-terminal acidic tail region is the core functional site
for this activity of the molecule. Moreover, the sensitivity
of different bacteria to HMGB1 varies greatly.
The antibacterial activity is a novel function of HMGB1.
Because of the new effect the cytoplasmal and extracellu-
lar HMGB1 have been considered an important part of
innate immunity defensive barrier of the human body in
physiological situation. The recent study shows that the
purified testicular HMGB1 has antibacterial activity,
which means this protein may function as a paracrine host
defense factor in the testis[26,27]. In addition, it has been
reported that the recombinant rat HMGB1 expressed by
prokaryotic system has similar antibacterial activity as
native human HMGB1[26]. However, no information is
available at present as to which region in HMGB1 is
mainly responsible for its antibacterial activity. In this
study we identified that the C-terminal acidic tail is the
key region for the antibacterial activity of HMGB1,
because both the full length rHMGB1 and C peptide alone
could efficiently inhibit bacteria proliferation, but
rHMGB1 A box and B box, and tHMGB1 lacking the C-ter-
minal acidic tail had no antibacterial function. Further-
more, we identified that the amino acid residues 201-205
in C-terminal acidic tail region may play a crucial role in
the antibacterial activity of HMGB1. Our finding would
be of helpful to define the antibacterial mechanisms of
HMGB1.
Because of the antibacterial activity it is difficult to express
high level HMGB1 with prokaryotic system. Previous
studies have shown the difficulties in expressing the mol-
ecule in E. coli, indicating that the choice of expressing
vector is crucial for the yield of recombinant
HMGB1[24,29]. It is reported that pQE-80L is suitable for
expressing toxic protein because there is no leaky expres-
sion before IPTG inducing. Therefore, this vector was used
in this study. Although we can get enough rHMGB1 for
the in vitro experiment, the expression level is still low no
matter how the expressional conditions were optimized.
However the proteins without antibacterial activity could
be highly expressed. Our results is consistent with the pre-
viously reports[24,29]. This phenomenon suggests that it
is necessary and important to develop novel expression
system for preparing abundant rHMGB1 for the in vivo
experiment. Moreover, as mentioned below, E. coli DH5
has the weakest sensitivity to HMGB1, which suggest that
besides the antibacterial activity of HMGB1 there may be
other reasons responsible for the low level expression of
the molecule.
Different bacteria may have a varied sensitivity to
HMGB1, so we carefully chose experimental bacteria
strains in this study. SA is a typical gram-positive cocci
Western blot analysis of the recombination proteins Figure 2
Western blot analysis of the recombination proteins. 
Identification of the expression of the His-tagged recom-
binant proteins in E. Coli DH5 by Western blot. 1, DHFR; 2, 
rHMGB1 A box; 3, rHMGB1 B box; 4, rHMGB1; 5, tHMGB1; 
6, mHMGB1 -211-215; 7, mHMGB1- 206-215; 8, mHMGB1 -
201-215; 9, mHMGB1 -196-215; 10, mHMGB1 -191-215; 11, 
mHMGB1 -186-200; 12, mHMGB1 -196-210; 13, mHMGB1 -
196-205; 14, mHMGB1 -198-207; 15, mHMGB1 -201-210; 
16, mHMGB1 -201-205.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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SDS-PAGE analysis of the recombination proteins Figure 3
SDS-PAGE analysis of the recombination proteins. Purity analysis of the recombinant proteins by SDS-PAGE. After 
purified by Ni2+-NTA chromatography the purity of the proteins were analyzed with SDS-PAGE. M, Molecular weight stand-
ards; 1, rHMGB1 A box; 2, rHMGB1 B box; 3, DHFR; 4, rHMGB1; 5, tHMGB1; 6, mHMGB1 -211-215; 7, mHMGB1 -206-215; 
8, mHMGB1 -201-215; 9, mHMGB1 -196-215; 10, mHMGB1 -191-215; 11, mHMGB1 -186-200; 12, mHMGB1 -196-210; 13, 
mHMGB1 -196-205; 14, mHMGB1 -198-207; 15, mHMGB1 -201-210; 16, mHMGB1 -201-205.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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genus[30]. E. coli is a large group of gram-negative rode
whose natural habitat is the intestinal tract. E. coli JM109
and DH5 are widely used in gene engineering today. E.
coli ATCC 25922 is the standard stain of E. coli. PA is a
medically important kind of gram-negative genus[31].
However, PA is resistant to all tested proteins. At present
we have no idea about the reasons why the antibacterial
effect of HMGB1 on different bacteria is varied.
Results from this study may also suggest that it has some
potential to develop antibacterial peptide based on C-ter-
minal acidic tail. Antibacterial peptides have been pro-
Antibacterial activity assay of rHMGB1, tHMGB1, rHMGB1 A box, B box, and C peptide with the method of dilution in the test  tubes Figure 4
Antibacterial activity assay of rHMGB1, tHMGB1, rHMGB1 A box, B box, and C peptide with the method of 
dilution in the test tubes. The antibacterial activities of rHMGB1, tHMGB1, rHMGB1 A box, B box, and C peptide were 
compared by the method of dilution in the test tubes as described in the Materials and Methods. The bacteria used in this 
experiment included SA, JM109, ATCC 25922, DH5 and PA. Each experiment was performed in triplicate and repeated three 
times. DHFR protein purified by the same system was used as a negative control. Data showed as mean ± standard deviation 
and were analyzed with One-Way ANOVA. * P < 0.05 vs control DHFR.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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Antibacterial activity assay of eleven different deleted mutants lacking different several amino acid residues in C-terminal acidic  tail region of HMGB1 with the method of dilution in the test tubes Figure 5
Antibacterial activity assay of eleven different deleted mutants lacking different several amino acid residues in 
C-terminal acidic tail region of HMGB1 with the method of dilution in the test tubes. The antibacterial activities of 
eleven different deleted mutants lacking different several amino acid residues in C-terminal acidic tail region of HMGB1 were 
compared by the method of dilution in the test tubes. The bacteria used in this experiment included SA, JM109, ATCC 25922, 
DH5 and PA. Each experiment was performed in triplicate and repeated three times. DHFR protein purified by the same sys-
tem was used as a negative control. Data showed as mean ± standard deviation and were analyzed with One-Way ANOVA. * 
P < 0.05 vs control DHFR.Journal of Biomedical Science 2009, 16:83 http://www.jbiomedsci.com/content/16/1/83
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posed as novel drugs to target different bacteria, so they
may have therapeutic implications for bacteria infec-
tions[32,33]. Our results showed that C-terminal acidic
tail alone (C peptide) could exert antibacterial function
and the amino acid residues 201-205 in C-terminal acidic
tail region plays a crucial role in antibacterial function of
HMGB1, which suggested that it may be possible to
design novel antibacterial peptides derived from C pep-
tide. The C-terminal acidic tail of HMGB1 is highly con-
servation, which composes of 30 residues entirely of
aspartic acid and glutamic acid residues. The sequence of
HMGB1 amino acid residues 201-205 is EDEED which are
all acidic amino acid residues but no data and references
for the reason why these residues, but not other C-termi-
nal residues, are important for HMGB1 antibacterial func-
tion so far. More studies are warranted regarding the
structure basis and molecular mechanism by which
HMGB1 plays antibacterial function.
Conclusion
This study suggests that the C-terminal acidic tail is the key
region for the antibacterial activity of HMGB1, and the
amino acid residues 201-205 in C-terminal acidic tail
region is the core functional site for this activity of
HMGB1.
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